Fibrosis-4 Index as a Predictor for Disease Severity and Mortality in Patients with COVID-19
Open Access
- 5 March 2023
- journal article
- research article
- Published by Online Turk Saglik Bilimleri Dergisi in Online Türk Sağlık Bilimleri Dergisi
- Vol. 8 (1) , 134-139
Abstract
Objective: The Fibrosis-4 (FIB-4) index is a noninvasive marker of liver fibrosis in various patient populations. We examined whether there is a relationship between the severity and prognosis of COVID-19 disease and the FIB-4 index. Materials and Methods: This stuy is a cross-sectional and retrospective. The patients were divided into two groups as those hospitalized in the intensive care unit (ICU) and those hospitalized in the clinic (non- ICU). Results: Of the total 158 cases,86(54%) were male. Age, total bilirubin, AST levels and FIB-4 index were higher in ICU patients compared to non-ICUs (p<0.001,p=0.002, p=0.003, p<0.001 respectively). FIB-4 index non-survivors were also higher (p=0.002). When the effect of the FIB-4 index on the severity of COVID-19 disease and mortality was evaluated by ROC analysis, both ICU and non-survivors were found to be significant (respectively FIB-4 score;AUC=0.705,95%CI:0.624-785,p<0.001;AUC=0.654,95%CI:0.566-742,p=0.002). When the FIB-4 index cut-off value for disease severity was taken as 2.19, 70.0% sensitivity and 60% specificity were found in predicting disease severity. Moreover, when the FIB-4 index cut-off value for mortality was taken as 2.19, 71.2% sensitivity and 53% specificity were found in predicting mortality. Conclusion: The FIB-4 index is an independent predictor of severity and mortality in COVID-19 patients requiring ICU.Keywords
Funding Information
- YOK
This publication has 25 references indexed in Scilit:
- Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisGastroenterology, 2020
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver DiseaseGastroenterology, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- A Novel Coronavirus from Patients with Pneumonia in China, 2019New England Journal of Medicine, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Screening for liver fibrosis in the general population: a call for actionThe Lancet Gastroenterology & Hepatology, 2016
- Hepatocytes: a key cell type for innate immunityCellular & Molecular Immunology, 2015
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevanceJournal of Hepatology, 2014
- Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patientsLiver International, 2010
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006